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Abstract
Background: Methylphenidate (MPH) is a psychostimulant that exerts its pharmacological effects via preferential blockade
of the dopamine transporter (DAT) and the norepinephrine transporter (NET), resulting in increased monoamine levels in
the synapse. Clinically, methylphenidate is prescribed for the symptomatic treatment of ADHD and narcolepsy; although
lately, there has been an increased incidence of its use in individuals not meeting the criteria for these disorders. MPH has
also been misused as a ‘‘cognitive enhancer’’ and as an alternative to other psychostimulants. Here, we investigate whether
chronic or acute administration of MPH in mice at either 1 mg/kg or 10 mg/kg, affects cell number and gene expression in
the basal ganglia.
Methodology/Principal Findings: Through the use of stereological counting methods, we observed a significant reduction
(,20%) in dopamine neuron numbers in the substantia nigra pars compacta (SNpc) following chronic administration of
10 mg/kg MPH. This dosage of MPH also induced a significant increase in the number of activated microglia in the SNpc.
Additionally, exposure to either 1 mg/kg or 10 mg/kg MPH increased the sensitivity of SNpc dopaminergic neurons to the
parkinsonian agent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Unbiased gene screening employing Affymetrix
GeneChipH HT MG-430 PM revealed changes in 115 and 54 genes in the substantia nigra (SN) of mice exposed to 1 mg/kg
and 10 mg/kg MPH doses, respectively. Decreases in the mRNA levels of gdnf, dat1, vmat2, and th in the substantia nigra
(SN) were observed with both acute and chronic dosing of 10 mg/kg MPH. We also found an increase in mRNA levels of the
pro-inflammatory genes il-6 and tnf-a in the striatum, although these were seen only at an acute dose of 10 mg/kg and not
following chronic dosing.
Conclusion: Collectively, our results suggest that chronic MPH usage in mice at doses spanning the therapeutic range in
humans, especially at prolonged higher doses, has long-term neurodegenerative consequences.
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Introduction
Methylphenidate (MPH; marketed under trade names Con-
certaH MetadateH, MethylinH, RitalinH) is one of the most
commonly prescribed stimulant medications for the symptomatic
management of ADHD and narcolepsy [1,2,3]. MPH has been
shown to have addictive potential, although it is not abused as
frequently as cocaine [4]. Recent studies havedetailed an increasing
incidence of MPH abuse among young adults and college students
in the United States, most likely for its purported non-therapeutic
benefit of cognitive enhancement also called ‘‘neuroenhancement’’.
TheMonitoringtheFutureStudy(MTF)reportedthat 2.7%ofhigh
school students reported a non-therapeutic use of MPH while 1.9%
of college students reported a similar non-medicinal usage [5,6]
In both diagnosed ADHD and non-ADHD populations, MPH
has been shown to increase scores on standardized tests [7,8], as
well as increase working memory [9] and thus, there have been
calls for making it available as an ‘‘over the counter’’ (OTC) drug
[10]. Despite the extensive use of this stimulant in ADHD and as
well as for ‘‘off-label’’ use, few papers have been published
regarding the long-term neurological consequences of MPH
exposure in the CNS.
MPH is a Schedule II CNS stimulant that exerts its
pharmacological effects via preferential blockade of the dopamine
transporter (DAT) and norepinephrine transporter (NET), similar
to that of cocaine [4]. This blockade results in a reduction of
dopamine/norepinephrine uptake, leading to an increase in post-
synaptic dopamine/norepinephrine levels [11,12]. Thus, MPH
usage leads to an acute increase in striatal dopamine levels [13]. In
terms of neurological effects, dopamine has been shown to have a
major modulatory effect in the developing brain on both
neostriatal and cortical neurogenesis [14,15]. Additionally, excess
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33693dopamine has been shown to be toxic both in vitro and in vivo due to
the production of superoxide, hydrogen peroxide, and the
dopamine quinone [16,17,18]. In fact, both acute and chronic
treatment with MPH has been shown to result in superoxide
production in the brain [19,20,21,22,23]. Free dopamine has also
been shown to induce an inflammatory response in the brain
characterized by an increase in cytokines and chemokines [24]
that lead to an induction of microgliosis.
In this study, we investigate whether long-term administration
of MPH in mice at two doses (1 mg/kg and 10 mg/kg) that
reproduce the therapeutic window in humans (treatment of
ADHD and recreational use/narcolepsy, respectively) [25,26,27]
can induce changes in the basal ganglia. Specifically, we examined
if acute or chronic administration of MPH altered SNpc dopamine
neuron number and catecholamine levels in the striatum. Since
excessive dopamine can induce oxidative stress and inflammation,
we examined if MPH rendered the basal ganglia more sensitive to
MPTP, an agent that has previously been shown to induce neuron
damage in the SNpc.
Results
Chronic MPH administration affects SNpc DA neuron
number
We conducted a systematic stereological analysis of the SNpc in
Swiss-Webster mice to determine if chronic exposure to saline,
1 mg/kg, or 10 mg/kg MPH for 90 days affected dopaminergic
(DA) neuron number (Fig. 1A–I). While no change in SNpc DA
neuron number was observed in animals treated with 1 mg/kg
MPH, we did observe a 20% reduction of SNpc DA neurons in
mice treated with 10 mg/kg MPH (Fig. 1J). The distribution of cell
loss demonstrated that DA neurons towards the caudal end of the
SN were more vulnerable to MPH effects while those residing in
the more rostral end of this structure appeared unaffected
(Fig. 1K).
Chronic MPH exposure results in microglia activation in
the SNpc
Since excess dopamine has been reported to induce oxidative
stress and inflammation, we examined whether chronic adminis-
tration of MPH could induce a pathological immunoligcal reaction
in response to chronic MPH in the SNpc. We estimated the total
number of Iba-1-positive microglia cells within the SNpc, and
based upon morphology, determined the proportion of microglia
in the resting and activated states. We observed that chronic
administration of 10 mg/kg MPH did not affect the number of
resting microglia (Fig. 2A), but did induce a significant increase in
activated microglia (Fig. 2B). We did not observe any change in
the number of resting or activated microglia after treatment with
1 mg/kg MPH (Fig. 2A,B).
Dopamine and dopamine turnover affected following
chronic MPH dosing
In order to determine if long-term administration of MPH
resulted in changes in total striatal dopamine levels or dopamine
turnover, striata were microdissected 7 days after mice had been
administered 90 days of saline, 1 mg/kg MPH, or 10 mg/kg
MPH. We found that long-term administration of 1 mg/kg, but
not 10 mg/kg MPH, induced a significant increase in total striatal
dopamine compared to saline-injected controls (Fig. 3A). We also
found a significant increase in the major dopamine metabolite 3,4-
dihydroxyphenylacetic acid (DOPAC) at both 1 mg/kg and
10 mg/kg compared to saline-treated mice (Fig. 3B). However, a
significant increase in dopamine turnover (DOPAC/DA) was
observed only at 10 mg/kg MPH (Fig. 3C).
Chronic MPH exposure sensitizes the SNpc to MPTP
effects
Given that chronic administration of 10 mg/kg MPH-admin-
istration lowers SNpc DA neuron number, we examined whether
chronic exposure to MPH increased the sensitivity of these
neurons to the parkinsonian agent 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP). We also examined if addition of
MPTP after MPH altered the immunological microglial response.
In terms of SNpc dopaminergic neuron loss, we have previously
shown that the Swiss-Webster strain is resistant to MPTP-induced
neuron loss [28,29]. Thus, if any SNpc neuron loss is observed, it
can be inferred that this was due to previous exposure to MPH.
We found that chronic administration of either 1 or 10 mg/kg
MPH sensitizes SNpc DA neurons to the effects of MPTP
compared with saline-injected controls. As shown in figure 1J,
MPTP induces an approximately 20% increase in cell death in
mice that received chronic administration of either 1 or 10 mg/kg
MPH.
We also examined the microglial response to MPTP in these
MPH-treated Swiss-Webster mice. Since we only observed an
increase in activated microglia in mice chronically-administered
10 mg/kg MPH (Fig. 2B), we only examined the immune response
to added MPTP in this condition. We found that mice
administered 10 mg/kg MPH+MPTP exhibit a significant de-
crease in the number of resting microglia (Fig. 2A), with a
concomitant rise in the number of activated microglia (Fig. 2B).
This suggests that the MPTP potentiates the immune response to
MPTP.
Although the increase in SNpc dopaminergic neuron loss was
not large enough in and of itself to result in the onset of
parkinsonism, this study does suggest that chronic administration
of MPH has the potential to be a predisposing or contributing
factor to disorders that lead to neurodegenerative disorders
involving the dopaminergic system.
Alterations in Gene Expression following Acute and
Chronic MPH Exposure in SN
In order to begin to identify the mechanism(s) underlying the
MPH-induced decrease in SNpc DA neuron number and
increases in CNS inflammation, we conducted an Affymetrix
gene array study to identify SNpc mRNA changes that were
induced in response to chronic administration of MPH. Using
unsupervised hierarchical clustering analysis, probes were selected
using a median absolute deviation score. Differentially expressed
genes between each treatment condition and controls were derived
using local-pooled-error test (LPE) with a FDR of 0.05 as the cut-
off. We found a total of 115 genes and 54 genes out of 45,037 on
the arrays whose expression were significantly different at the
p#0.05 at 1 and 10 mg/kg MPH doses, respectively, in the SNpc
(Tables S1 and S2). Of these gene changes, 23 were common
between the high and low MPH doses (Fig. 4A). Since the cellular
changes, both in SNpc DA neuron number and microglia, were
observed primarily at the 10 mg/kg MPH dose, we used qPCR to
further examine and validate the expression of genes in animals
exposed to only this dose. Specifically, we examined expression of
genes associated with modulations in basal ganglia toxicity
including brain derived neurotropic factor (bdnf), glial derived
neurotropic factor (gdnf), tyrosine hydroxylase (th), the dopamine
transporter DAT1 (slc6a3), and the vesicular monoamine trans-
porter VMAT2 (slc18a2). We found significant reductions in
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and chronic administration of 10 mg/kg MPH, while bdnf was
only reduced after chronic 10 mg/kg MPH (Fig. 4B–E).
Evidence for inflammation associated with acute doses of
MPH
Due to the observed increase in the number of morphologically-
activated SNpc microglia following administration of 10 mg/kg
MPH, we investigated whether the expression of inflammatory
genes, including il-6, tnf-a, cox-2, and il-1b were altered following
chronic or acute dosing of 10 mg/kg MPH in both SN and its
target, the striatum. We found significant increases in mRNA
expression of the pro-inflammatory genes tnf-a and il-6 in the
striatum of animals administered a single dose of 10 mg/kg MPH
compared saline-injected controls (Fig. 5A–D). No changes were
seen in the expression of these genes in the SN.
Discussion
The present study investigated the pathological effects of acute
and chronic MPH in the basal ganglia using two different doses
that span the therapeutic window of MPH use for ADHD and
Figure 1. Chronic MPH administration affects SNpc dopamine neuron numbers and induces microgliosis. Representative images of the
substantia nigra pars compacta (SNpc) from brains of animals treated with either saline (A–C), 1 mg/kg MPH (D–F) or 10 mg/kg MPH(G–I). The images
presented are at 46,2 0 6 and 1006, respectively. The brain sections have been immunostained with anti-TH (brown) to identify dopaminergic
neurons and anti-Iba-1 (purple) to identify microglia. (J) Stereological estimates of dopamine neuron number in substantia nigra pars compacta
(SNpc) in animals administered saline (ctrl), saline+MPTP (ctrl+MPTP), 1 mg/kg MPH, 1 mg/kg MPH+MPTP, 10 mg/kg MPH and 10 mg/kg MPH+MPTP.
Saline, 1 mg/kg MPH and 10 mg/kg were administered for 90 days following a one-week drug washout period before 4620 mg/kg MPTP was
injected (n=10). (K) The distribution of dopamine neurons along the rostral-caudal axis in SNpc following chronic administration (90 days) of saline
(control), 1 mg/kg MPH and 10 mg/kg MPH. **p#0.01 compared to saline-treated controls; ***p#0.001 10 mg/kg MPH compared to saline-control
(ctrl), control+MPTP (ctrl+MPTP) and 1 mg/kg MPH+ no MPTP (n=10). One-way ANOVA statistical test was performed to draw comparisons between
the different groups followed by Bonferroni post-hoc tests. Scale bars (A,D,G), 200 mms; (B,E,H), 40 mms and (C,F,I), 8 mms.
doi:10.1371/journal.pone.0033693.g001
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[30,31]. We demonstrate that chronic administration of 10 mg/kg
MPH induces a small but significant loss of SNpc dopaminergic
neurons. We also find that chronic exposure to both 1 mg/kg and
10 mg/kg MPH can sensitize SNpc dopamine neurons to a
further oxidative stress. Though the complete mechanism for this
sensitization of dopamine neurons is not well understood, our
experiments suggest a combined effect of an increased inflamma-
tory response with reduced levels of several trophic factors,
including BDNF and GDNF.
Despite the extensive use of MPH in school aged and adult
populations with ADHD (including a proportion that are
improperly diagnosed with ADHD) [32,33]) as well its use in
general cognitive enhancement in non-ADHD individuals [10],
only a few studies have investigated the neuropathological
consequences of long-term MPH exposure. In this study, we used
a 12-week MPH administration schedule that spans the develop-
mental period in rodents and corresponds to the pre-adolescent
through young adult period in humans, during which MPH is
typically used [34].
MPH’s mechanism of action is to increase the availability of
extracellular DA and NE in the synaptic cleft through blockade of
the dopamine transporter (DAT) and norepinephrine transporter
(NET) [12,35,36]. In this study, we observed a significant increase
in total dopamine levels in the striatum at 1 mg/kg MPH, a
change that was not observed at 10 mg/kg MPH. Previous studies
have also reported a similar increase in striatal dopamine levels at
similar lower doses of MPH [37]. The observed lack of change in
total dopamine concentrations at the higher dose might reflect a
ceiling effect achieved due to chronic dosing of the drug, or it may
be the result of a compensatory alteration in the production of
dopamine that results from the observed 20% loss in dopamine
neurons in the SNpc. In order to determine if this compensation is
occurring, we measured the ratio of striatal dopamine to SNpc DA
neurons. When examined as a ratio, both 1 and 10 mg/kg MPH
treatment demonstrate a significant increase in the dopami-
ne:SNpc neuron ratios (150% in 1 mg/kg MPH and a 132%
increase for mice treated with 10 mg/kg MPH), suggesting that
either dose of MPH increases striatal dopamine, not just that of
1 mg/kg MPH.
It is well known that increased extracellular DA may be
problematic. Oxidation of DA can produce both superoxide and
hydrogen peroxide, which may then form hydroxyl radicals in the
presence of certain metals [17]. Additionally, previous studies have
indicated that DA can become neurotoxic following its oxidation
to a DA quinone, which may then react with cellular thiols to form
5-S-glutathionyl DA and 5-S-cysteinyl DA [38]. The subsequent
oxidation of 5-S-cysteinyl DA produces a number of neurotoxic
compounds [17]. An increase in the free radical content in the
basal ganglia has been shown to potentiate neurodegeneration
[39,40,41].
In addition to a direct effect of MPH on the basal ganglia, we
hypothesized that chronic MPH could increase sensitivity of SNpc
dopamine neurons to a later oxidative stress exposure. MPH’s
mechanism of action- blockade of the DAT- is similar to that of
cocaine [42] and results in an increase in extracellular dopamine,
which has been shown to quickly form free radical adducts
[43,44]. Since increased free radical production has been shown to
increase the sensitivity of SNpc neurons to environmental or
administered xenobiotics [42], it is possible that long-term MPH
could be a contributing etiological factor in a multi-hit hypothesis
for induction of Parkinson’s disease [45,46,47].
In this study, we administered an acute regimen of MPTP
(4620 mg/kg), an agent that is known to induce oxidative stress
[48,49,50], to MPTP-resistant Swiss-Webster mice [28] treated
with a chronic regimen of 1 or 10 mg/kg MPH. We found that
chronic exposure to both 1 mg/kg and 10 mg/kg MPH increased
the sensitivity of SNpc dopamine neurons to oxidative stress, based
on a significantly increased SNpc dopamine neuron loss in mice
administered MPH as compared to saline-treated control mice.
Although the mechanism for this neuronal loss is unknown, a
significant increase in MPH-induced activated microglia was
observed; therefore, we hypothesize that an increase in free radical
formation along with a concomitant neuroinflammatory response
increases the sensitivity of the SNpc dopamine neurons to a later
oxidative challenge. This conclusion is supported by a recent
Figure 2. Chronic exposure to high dose MPH results in microglial cell activation in the SNpc. Stereological estimates of Iba-1 positive
microglia cells in the SNpc (A) the total number of morphologically-resting microglia and (B) the total number of morphologically-activated microglia
following chronic administration of either saline (ctrl), 1 mg/kg MPH, 10 mg/kg MPH and 10 mg/kg MPH+MPTP. (n=5). One-way ANOVA statistical
test was performed to draw comparisons between the different groups followed by Bonferroni post-hoc tests.
doi:10.1371/journal.pone.0033693.g002
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usage, which like MPH results in higher levels of striatal dopamine
in the synaptic cleft, results in a significantly higher risk for
developing Parkinson’s disease [51].
In order to address the mechanism for increased sensitivity of
dopamine neurons, we used an unbiased gene microarray analysis.
A comparison of heat maps representative of relative mRNA
expression (Figure 4A,B) shows a number of genes whose direction
of expression change (6) was similar after chronic administration
of 1 and 10 mg/kg. Gene Set Enrichment Analysis (GSEA)
identified gene sets that were related to inflammation and cell
damage and repair pathways. Using qPCR validation, we
measured significant decreases in mRNA expression of the
neurotrophins bdnf and gdnf in the SNpc after both acute and
chronic dosing of 10 mg/kg MPH. We also found significant
decreases in mRNA expression of genes involved in dopamine
biosynthesis (tyrosine hydroxylase, th) and handling (dopamine
transporter, (slc6a3) and the vesicular monoamine transporter
(slc18a2)). These changes were observed following both acute and
chronic doses of 10 mg/kg MPH in the SNpc. Previous reports
have associated decreases in mRNA expression of vmat2 and dat1
with neurotoxicity in cases where pharmacotherapeutic agents that
alter dopamine levels and neurodegenerative conditions, respec-
tively [52,53]. The observed downward changes in the mRNA
message of dat1 and th may also be due to the covalent
modification by dopamine quinones leading to its translational
inactivation [41,54,55].
Notably, our Affymetrix and qPCR studies also found that acute
exposure to higher doses of MPH increased the expression of
inflammatory genes in the striatum, including the pro-inflamma-
tory genes tnf-a and il-6. This increase in the pro-inflammatory
gene expression following a single acute dosage suggests that MPH
does induce inflammation, and this is supported by our finding of
increased numbers of both total and activated microglial cells in
the SNpc. Surprisingly, we did not see an increase in inflammatory
gene expression after chronic administration of MPH, although we
did continue to observe an increased number of morphologically
activated microglia. This suggests that sometime during the course
of the chronic exposure to MPH, there might be a dampening
(self-repressesion) of inflammatory gene expression. It is unknown
at this time if the gene repression we observe after chronic
treatment with MPH is permanent (longer than 90 days), or if it
can at a later time be re-induced. If this is the case, then the
activated microglia observed, have the potential to play a
modulatory role in later inductions of oxidative stress that would
affect the same brain systems. Alternatively, it is also possible that
microglia that are activated do not have the ability to return to
their morphologically pre-inflamed state, as other studies have
shown evidence of microglia activation long after resolution of the
initiating insult [56].
Taken together, our results suggest that chronic administration
of methylphenidate in mice, at doses that approximate those at the
higher therapeutic range in humans, results in a reduced
expression of neurotrophic factors, increased neuroinflammation,
and a small, but significant loss of SNpc dopamine neurons. These
results can only be interpreted in the context on normal brain
structure and function, and thus would have direct implications for
the illicit/neurocognitive use of MPH. Since the underlying
anatomy and biochemistry of ADHD has not been definitively
characterized, our findings may or may not be generalizable to the
vast majority of humans who are properly diagnosed with ADHD
and are prescribed methylphenidate. Nevertheless, this work
supports studies [51,57,58,59] that demonstrate that drugs shown
to increase the levels of dopamine in the synaptic cleft can
contribute to degenerative changes in the basal ganglia.
Materials and Methods
Ethics Statement
All of the experimental procedures in the animals were
performed in accordance with the NIH Guide for the Care and
Use of Laboratory Animals. These studies were carried out under
protocol number 322 and were approved by the St Jude Children’s
Research Hospital IACUC under the auspices of Animal
Assurance Number: A3077-01, effective March 5, 2010–Dec.
31, 2013.
Animal Handling and Treatment
Three week old Swiss Webster mice (Hsd:ND4, Harlan
Laboratories) were acclimated in our animal facility for a period
of a week and maintained on a 12 h light/dark cycle with ad libitum
food and water. Starting at postnatal day PD28, mice were
Figure 3. Chronic MPH dosing alters dopamine turnover in the
striatum. Striata were microdissected from the brains of mice
administered 90 days of saline (Ctrl), 1 mg/kg MPH or 10 mg/kg MPH
and were processed for HPLC analyses. Total striatal levels of (A)
dopamine and (B) the dopamine metabolite 3,4-dihydroxyphenylacetic
acid (DOPAC) are presented as percentage of saline-treated controls
(Ctrl). (C) Dopamine turnover is presented as the ratio of DOPAC/DA.
*p#0.01 compared to saline-controls (Ctrl) (n=8). One-way ANOVA
statistical test was performed to draw comparisons between the
different groups followed by Bonferroni post-hoc tests.
doi:10.1371/journal.pone.0033693.g003
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10 mg/kg methylphenidate hydrochloride (MPH, Cat # M2892
Sigma-Aldrich), once daily, 1 hour prior to the initiation of the
animal’s active phase (18:00 hrs). The doses of MPH used in this
study were chosen based on previous studies in rodents suggesting
that MPH doses of less than 5 mg/kg i.p. mirror those that are
used in clinical practice [26], whereas recreational use of MPH or
its use in the treatment of narcolepsy would be reflected by a dose
of 10 mg/kg [27]. MPH injections were administered using a
school week schedule (5/days/week), as this dosing paradigm is a
recommended schedule for administration of MPH to eliminate
the possibility of MPH to abrogate growth [60,61]. At the end of
12 weeks, the animals were allowed a washout period of 7 days
(except when noted) to ensure complete elimination of MPH from
the CNS [62]. Subsequently, mice were either transcardially
perfused with 3% paraformaldehyde for histological studies, or
rapidly decapitated following an induction of deep anesthesia,
after which individual brain regions were dissected and processed
for mRNA isolation.
Identification and Dissection of Brain Structures
Brain tissue from mice was dissected based on the following
coordinates: SN (Bregma: 22.70 to 23.70) and striatum (Bregma:
+0.14 to +1.26 mm) [63].
Immunohistochemistry
After a one week drug washout period, Swiss-Webster mice
were deeply anesthetized with an overdose of Avertin; following
the loss of the deep tendon and corneal reflexes, mice were
transcardially perfused with cold physiological saline followed by
cold 3% paraformaldehyde. The perfused brains were processed
for paraffin embedding. Brains were sectioned on the microtome
at 10 mm thickness and mounted on polyionic slides (Superfrost-
plus, Fisher Scientific). Deparaffinized sections were incubated
with primary antibody for identification of dopamine neurons
(mouse monoclonal anti-tyrosine hydroxylase, TH; Sigma-Al-
drich;1:500) or dopaminergic neurons and microglia (mouse
monoclonal anti-tyrosine hydroxylase and rabbit polyclonal Iba-
Figure 4. Acute and chronic administration of MPH alters gene expression in the substantia nigra (SN). (A) Heat map representation of
gene expression changes following chronic administration of either 1 mg/kg MPH or 10 mg/kg MPH in the SN (n=3). qPCR analysis demonstrating
normalized fold-change expression of (B) bdnf, (C) gdnf, (D) dat1(slc6a3), (E) vmat2(slc18a2) and (F) th mRNA in SN (n=3). *p#0.02 vs saline-controls
(ctrl); **p#0.02 vs saline-controls and 10 mg/kg MPH-acute dose; #p#0.02 10 mg/kg MPH acute-dose vs saline-controls (ctrl). One-way ANOVA
statistical test was performed to draw comparisons between the different groups followed by Bonferroni post-hoc tests.
doi:10.1371/journal.pone.0033693.g004
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biotinylated mouse IgG (for TH, 1:1000) or biotinylated rabbit
IgG (for Iba-1, 1:1000). Diaminobenzindine (DAB) or a VIP kit
(Vector labs) reaction was used to yield a brown (TH) or a purple
(Iba-1) color, respectively. All tissue sections were counter stained
with the nissl stain Neutral Red for landmark identification.
Quantification of SNpc DA neurons and Iba-1-positive
microglia
DA neuron and Iba-1-positive microglial cell number in the
SNpc were estimated using standard model-based stereological
methods [64]. Briefly, for neuronal counts, brains were blocked
and serially-sectioned at 10 mm from the rostral hippocampus to
the cerebellar-midbrain junction. Serial sections were mounted 5
sections per slide onto polyionic slides. TH-positive neurons and
TH-negative, Nissl-positive cells within the SNpc that had the
characteristics of dopaminergic neurons were counted using a 406
objective (total magnification 4006). Specifically, neurons from
both left and right sides of the SNpc within one section per slide
(chosen randomly and then maintained throughout all sections,
(i.e. the 3
rd section on each slide) were counted) [64].
Microglia were counted using the optical fractionator method
[65] using Microbrightfield StereoInvestigator (MBF Biosciences,
Williston, VT). Both Iba-1 resting and activated microglia were
counted [66]. Stringent measures were adopted to classify Iba-1
positive microglia as resting or activated based on morphology
based on the detailed description by Graeber and Streit [67].
Microglial cells would be deemed as resting if they contained a
small oval Iba-1-positive cell body that averaged 3 microns in
diameter with long slender processes. Microglia would be classified
as activated when the cell body was slightly increased in size
compared to resting microglia and had an irregular shape. Based
on cell size of the counting particle in 12 micron (empirically
measured) sections, we used a high NA lens and a total
magnification of 10006 in which we were able to clearly define
approximately 18 focal planes within our section (1 focal plane
equals approximately 0.54 mm). The processes on the microglia
were shorter and had thickened processes. All numbers are
expressed as mean 6 SEM.
MPTP treatment
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP-HCl,
Cat. #M0896, Sigma-Aldrich, St. Louis, MO) was dissolved in
sterile saline to a final concentration of 5 mg/ml. Each animal was
administered four intraperitoneal injections of 20 mg/kg MPTP-
HCl, one every 2 hours for 8 hours. All mice were allowed to
survive for one week after MPTP injections, a time when the
MPTP-induced lesion was maximal [42].
Microarray Analysis
Animals injected with either saline, 1 mg/kg MPH, or 10 mg/
kg MPH for 3 months using a school-day schedule were allowed a
7 day drug wash period, after which animals were rapidly
decapitated under deep anesthesia. The substantia nigra (SN) was
rapidly dissected, flash frozen, and stored at 280uC. mRNA was
isolated from SN in accordance with the protocol outlined in
RNAqueousH-Micro kit (Ambion, Austin, TX) according to
manufacturers recommendations. Technical procedures for mi-
croarray analysis, including quality control of mRNA, labeling,
hybridization and scanning of the arrays were performed by the
Hartwell Center for Bioinformatics & Biotechnology (HC) at St.
Jude Children’s Research Hospital (SJCRH) according to standard
operating procedures for Affymetrix protocols (GeneChipH
Expression Analysis manual, Affymetrix, Santa Clara CA, USA).
The mRNAs were profiled using Affymetrix HT MG-430 PM
arrays. The array signals were normalized using Robust Multichip
Average [68] and batch-effect of three replicates were corrected
using ComBat [69]. The processed data were analyzed using
linear models algorithm with Limma [70]. Differentially expressed
genes between the treated and control samples were selected using
Figure 5. mRNA expression of pro-inflammatory genes following acute administration of 10 mg/kg MPH in the striatum. Fold change
values in mRNA expression presented are normalized against saline controls, in the striatum. The genes probed for include (A) il-6, (B) tnf-a ´, (C) cox2
and (D) il-1b.* p #0.02 compared to saline-controls (ctrl); **p#0.02 compared to 10 mg/kg MPH-chronic dose, (n=3). One-way ANOVA statistical test
was performed to draw comparisons between the different groups followed by Bonferroni post-hoc tests.
doi:10.1371/journal.pone.0033693.g005
Effects of Methylphenidate in Basal Ganglia
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33693FDR-corrected p-value of 0.01(q value of #0.05). All data are
MIAME compliant, and the raw data have been deposited in a
MIAME compliant database (GEOID: GSE33619).
Validation of Microaray Data and Quantitative Analysis of
mRNA levels
Dissected substantia nigra and striatum were homogenized and
processed to yield mRNA in accordance with the protocol outlined
in RNAqueousH-Micro kit (Ambion, Austin, TX). The isolated
RNA was converted to cDNA using the High Capacity RNA to
cDNA kit (Applied Biosystems, Carlsbad, CA). The cDNA was
subsequently used for qPCR analysis using a Taqman assay
(Applied Biosystems). The ribosomal 18S and beta-actin genes
were used as the standardizing control gene. The final values have
been expressed as 2
2DDCt denoting fold-change in mRNA levels
for each gene.
Statistical Analysis
One-way ANOVAs with Bonferroni post-hoc tests were used to
draw comparisons between treatment groups. Data was plotted as
mean 6 S.E.M. A value of p#0.05 was considered significant.
Supporting Information
Table S1 Identification of differentially expressed
genes (p#0.05) in the substantia nigra comparing saline
and 1 mg/kg MPH-treated mice.
(XLS)
Table S2 Identification of differentially expressed
genes (p#0.05) in the substantia nigra comparing saline
and 10 mg/kg MPH-treated mice.
(XLS)
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